377 A Randomized, Double-Blind, Placebo-Controlled Trial with a Novel Dual Noradrenergic Reuptake Inhibitor (NARI) and 5-HT3 Antagonist: Results of a Phase II 8-Week Study in Female Patients with Diarrhea Predominant Irritable Bowel Syndrome (D-IBS)

✍ Scribed by William G. Paterson; Jonathon Springer; Michael O'Mahony; Richard P. Reynolds; Subhas C. Ganguli; Brian Feagan; Suhail Nurbhai; Steven B. Landau

• Book ID: 119428115
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 95 KB
• Volume: 134
• Category: Article
• ISSN: 0016-5085
• DOI: 10.1016/s0016-5085(08)60240-1